MEI Pharma MEI Pharma Reports First Quarter Fiscal Year 2019 Results and Operational Highlights -- MEI on Track to Initiate ME-401 Phase 2 Accelerated Approval Study Around Year-End -- Thu, 08 Nov 2018 13:00:00 -0800 MEI Pharma To Present at Stifel 2018 Healthcare Conference Tue, 06 Nov 2018 05:00:00 -0800 MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan MEI to Receive $10 Million Upfront Payment, Plus Milestones and Tiered Royalty Payments Mon, 05 Nov 2018 05:00:00 -0800 MEI Pharma to Present Clinical Data from Three Oncology Programs at the 2018 American Society of Hematology (ASH) Annual Meeting Thu, 01 Nov 2018 06:00:00 -0700 MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies Thu, 11 Oct 2018 03:00:00 -0700